Repligen Corporation (NASDAQ:RGEN) was upgraded by stock analysts at BidaskClub from a “hold” rating to a “buy” rating in a report issued on Wednesday.

Several other analysts also recently weighed in on RGEN. Zacks Investment Research downgraded Repligen Corporation from a “buy” rating to a “hold” rating in a research report on Tuesday, June 6th. First Analysis reiterated an “equal weight” rating and issued a $40.00 price objective on shares of Repligen Corporation in a research report on Friday, April 21st. William Blair assumed coverage on Repligen Corporation in a research report on Friday, July 21st. They issued an “outperform” rating for the company. Jefferies Group LLC reiterated a “hold” rating and issued a $40.00 price objective (up previously from $33.00) on shares of Repligen Corporation in a research report on Wednesday, June 28th. Finally, Janney Montgomery Scott boosted their price objective on Repligen Corporation from $42.00 to $47.00 in a research report on Friday, June 23rd. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $41.20.

Shares of Repligen Corporation (NASDAQ RGEN) traded down 0.05% on Wednesday, reaching $42.76. 112,968 shares of the company were exchanged. The firm has a market capitalization of $1.46 billion, a PE ratio of 112.82 and a beta of 1.30. The stock’s 50-day moving average is $41.52 and its 200 day moving average is $36.21. Repligen Corporation has a 12-month low of $26.16 and a 12-month high of $46.81.

Repligen Corporation (NASDAQ:RGEN) last announced its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported $0.20 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.15 by $0.05. Repligen Corporation had a return on equity of 9.90% and a net margin of 15.61%. The firm had revenue of $32.40 million during the quarter, compared to the consensus estimate of $31.72 million. During the same quarter in the previous year, the company posted $0.16 earnings per share. The business’s revenue was up 11.0% on a year-over-year basis. On average, analysts forecast that Repligen Corporation will post $0.58 EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://www.dailypolitical.com/2017/08/09/repligen-corporation-rgen-upgraded-at-bidaskclub.html.

Several institutional investors have recently made changes to their positions in the stock. US Bancorp DE increased its position in shares of Repligen Corporation by 1.2% in the second quarter. US Bancorp DE now owns 4,629 shares of the biotechnology company’s stock worth $191,000 after buying an additional 54 shares in the last quarter. State of Alaska Department of Revenue increased its position in shares of Repligen Corporation by 2.2% in the first quarter. State of Alaska Department of Revenue now owns 3,740 shares of the biotechnology company’s stock worth $131,000 after buying an additional 80 shares in the last quarter. Arizona State Retirement System increased its position in shares of Repligen Corporation by 0.6% in the second quarter. Arizona State Retirement System now owns 17,726 shares of the biotechnology company’s stock worth $735,000 after buying an additional 100 shares in the last quarter. NBW Capital LLC increased its position in shares of Repligen Corporation by 0.5% in the first quarter. NBW Capital LLC now owns 22,655 shares of the biotechnology company’s stock worth $797,000 after buying an additional 118 shares in the last quarter. Finally, Louisiana State Employees Retirement System increased its position in shares of Repligen Corporation by 1.5% in the first quarter. Louisiana State Employees Retirement System now owns 13,800 shares of the biotechnology company’s stock worth $486,000 after buying an additional 200 shares in the last quarter. Institutional investors own 99.02% of the company’s stock.

Repligen Corporation Company Profile

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with MarketBeat.com's FREE daily email newsletter.